GnRH agonists: US FDA reviews CV safety

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1300, 2010-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of GnRH agonists and antagonists

By Tarlatzis Basil C   Bili Helen  

Expert Opinion on Drug Safety, Vol. 3, Iss. 1, 2004-01 ,pp. : 39-46

Informa Healthcare

Access to resources Recommend Favorite

Direct ovarian effects and safety aspects of GnRH agonists and antagonists

By Tarlatzis BC   Kolibianakis EM  

Reproductive BioMedicine Online, Vol. 5, Iss. 3, 2002-11 ,pp. : 8-13

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action

By Ortmann O   Weiss JM   Diedrich K  

Reproductive BioMedicine Online, Vol. 5, Iss. 3, 2002-11 ,pp. : 1-7

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

US FDA reviews safety of Stalevo

By  

Reactions Weekly, Vol. 1, Iss. 1297, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS

By Vrtačnik-Bokal Eda   Virant Klun Irma   Verdenik Ivan  

Reproductive BioMedicine Online, Vol. 18, Iss. 1, 2009-01 ,pp. : 21-28

Reproductive Healthcare Ltd

Access to resources Recommend Favorite